Anti-SRP Ab (Signal Recognition Particle Antibody), as measured by reference laboratories such as RDL (Reference Diagnostics Laboratory), is a highly specific serological marker crucial in the diagnosis and management of autoimmune myopathies, particularly Polymyositis and Dermatomyositis. The signal recognition particle (SRP) is a cytoplasmic ribonucleoprotein involved in the translocation of secretory and membrane proteins. In autoimmune contexts, the immune system aberrantly produces antibodies against SRP, leading to muscle inflammation and damage. The presence of Anti-SRP Ab is often associated with a distinct clinical phenotype characterized by acute onset, severe muscle weakness, and a resistance to standard immunosuppressive therapies. Patients with high titers of Anti-SRP Ab typically exhibit more pronounced muscle involvement and may have a higher risk of cardiac complications. The detection of these antibodies is performed using immunological assays, which are essential for accurate diagnosis and can aid in prognosticating the disease course. Anti-SRP Ab is also valuable in differentiating between various types of inflammatory myopathies, guiding targeted therapy. In research, the role of Anti-SRP Ab in the pathogenesis of autoimmune myopathies is an area of ongoing study, providing insights into the complex interplay between immune dysregulation and muscular pathology.
Anti-SRP Ab (RDL)
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →
All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.